FASLG Protein - Fas Ligand

FASLG Protein - Fas Ligand

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FASLG Protein - Fas Ligand</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Fas-Fc fusion protein</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Anti-FasL antibodies</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Caspase inhibitors</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Research</td>
</tr>
</table>

Pathway Diagram

FASLG Protein - Fas Ligand

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FASLG Protein - Fas Ligand</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Fas-Fc fusion protein</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Anti-FasL antibodies</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Caspase inhibitors</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Research</td>
</tr>
</table>

Pathway Diagram

Faslg Protein Fas Ligand is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div style="background:#f8f9fa;border:1px solid #ddd;padding:15px;border-radius:5px;margin:10px 0;"> [@fasla]
<h3 style="margin-top:0;">FASLG Protein - Fas Ligand</h3> [@dopaminergic]
<table style="width:100%;font-size:14px;"> [@motor]
<tr><td style="padding:5px;font-weight:bold;">Symbol</td><td style="padding:5px;">FASLG</td></tr> [@faslb]
<tr><td style="padding:5px;font-weight:bold;">Protein Name</td><td style="padding:5px;">Fas Cell Surface Death Receptor Ligand</td></tr> [@targeting]
<tr><td style="padding:5px;font-weight:bold;">Aliases</td><td style="padding:5px;">FasL, CD95L, APT1LG1</td></tr> [@soluble]
<tr><td style="padding:5px;font-weight:bold;">Molecular Weight</td><td>26 kDa (membrane), 17 kDa (soluble)</td></tr> [@faslc]
<tr><td style="padding:5px;font-weight:bold;">Protein Family</td><td>TNF Superfamily</td></tr>
<tr><td style="padding:5px;font-weight:bold;">Receptor</td><td>FAS (CD95)</td></tr>
<tr><td style="padding:5px;font-weight:bold;">Associated Diseases</td><td>AD, PD, ALS, HD, Stroke, Autoimmune Disorders, Cancer</td></tr>
</table>
</div>

Overview

FASLG (Fas Ligand), also known as FasL or CD95L, is a member of the TNF (Tumor Necrosis Factor) superfamily of cytokines. It is a type II transmembrane protein that binds to FAS (CD95), a death receptor on the cell surface. The FASLG-FAS interaction triggers [apoptosis](/entities/apoptosis) through the extrinsic programmed cell death pathway. In the central nervous system, FASLG plays critical roles in neuronal development, immune privilege, and neuroinflammation. Dysregulation of this pathway contributes to neuronal loss in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.

Molecular Structure

FASLG exists in two forms:

• Membrane-bound FASLG (mFasL): 26 kDa, type II transmembrane protein
• Soluble FASLG (sFasL): 17 kDa, generated by metalloproteinase cleavage

Structural Features

• TNF homology domain (THD) at C-terminus
• Forms homotrimers (biologically active)
• Pre-ligand assembly domain (PLAD) for receptor clustering

Molecular Function

Apoptosis Induction

• Binds to FAS (CD95) receptor on target cells
• Triggers formation of death-inducing signaling complex (DISC)
• Activates caspase-8, then caspase-3
• Leads to apoptotic cell death

Immune Regulation

• Cytotoxic T lymphocyte-mediated cell killing
• Immune privilege in eye and brain
• Regulation of activated T cells (activation-induced cell death)
• Control of inflammatory responses

Non-apoptotic Functions

• [NF-κB](/entities/nf-kb) activation (pro-survival signaling)
• Cell proliferation and differentiation
• Inflammatory cytokine production
• Wound healing

Expression Pattern

CNS Expression

• Activated [microglia](/cell-types/microglia-neuroinflammation): High expression
• [Astrocytes](/entities/astrocytes): Moderate expression
• [Neurons](/entities/neurons): Constitutive low, stress-induced
• T cells infiltrating CNS

Peripheral Expression

• Activated T cells, NK cells
• Cytotoxic T lymphocytes
• Some tumor cells
• Immune-privileged tissues

Role in Disease

Alzheimer's Disease

• Neuronal apoptosis
• Synaptic loss
• Microglial activation
• [Amyloid-beta](/proteins/amyloid-beta) toxicity

Parkinson's Disease

• [Microglia](/entities/microglia)-induced apoptosis
• Mitochondrial dysfunction
• [Neuroinflammation](/mechanisms/neuroinflammation)

Amyotrophic Lateral Sclerosis

Huntington's Disease

• Medium spiny neuron degeneration
• Mutant [huntingtin](/proteins/huntingtin-protein) toxicity
• Glial activation

Stroke and Ischemia

Autoimmune Disorders

Cancer

Therapeutic Targeting

Animal Models

• FasL-deficient mice (lpr mice): Lymphoproliferation, autoimmunity
• Fas transgenic mice: Altered apoptosis
• Neuron-specific FasL: Neurodegeneration models

Background

The study of Faslg Protein Fas Ligand has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future r

• [Apoptosis Pathway](/mechanisms/apoptosis-neurodegeneration)# See Also
• [Apoptosis Pathway](/mechanisms/apoptosis-neurodegeneration) [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• Caspase-3
• FAS Gene

External Links

• [UniProt: FASLG](https://www.uniprot.org/uniprot/P48023)
• [NCBI Gene: FASLG](https://www.ncbi.nlm.nih.gov/gene/3564)
• [GeneCards: FASLG](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FASLG)
• [OMIM: FASLG](https://www.omim.org/entry/134638)

References